Skip to Main content Skip to Navigation
Master Thesis

L'isatuximab dans le traitement du myélome multiple

Abstract : Multiple myeloma is a mature B-cell hematologic malignancy characterized by the proliferation of plasma cells producing a monoclonal immunoglobulin that can be detected in the blood or urine. It is a cancer that originates in the bone marrow, within the plasma cells. Plasma cells are a type of white blood cell that make immunoglobulins (antibodies) to fight infection. The bone marrow is a soft, spongy tissue in the bone where different types of blood cells are produced. In multiple myeloma there is an accumulation of abnormal plasma cells in the bone marrow, which prevents other blood cells from developing normally, causing anemia and asthenia or even imbalances in the amount of minerals in the body. Isatuximab is an anti-CD38 monoclonal antibody used in the treatment of Multiple Myeloma. It is an apoptotic inducer of Multiple Myeloma malignant cells through mechanisms of complementdependent cell lysis, antibody-dependent cell cytotoxicity, antibody-dependent cell phagocytosis by macrophages, but also through direct mechanisms of cell death induction. It also has immunomodulatory effects related to the elimination of immunosuppressive immune cells that express CD38.
Document type :
Master Thesis
Complete list of metadata

https://dumas.ccsd.cnrs.fr/dumas-03449851
Contributor : Ufr Santé Unicaen Connect in order to contact the contributor
Submitted on : Thursday, November 25, 2021 - 4:27:23 PM
Last modification on : Wednesday, December 15, 2021 - 3:48:05 AM

File

GERVAIS-Thomas.pdf
Files produced by the author(s)

Identifiers

  • HAL Id : dumas-03449851, version 1

Citation

Thomas Gervais. L'isatuximab dans le traitement du myélome multiple. Sciences pharmaceutiques. 2021. ⟨dumas-03449851⟩

Share

Metrics

Les métriques sont temporairement indisponibles